Ignite Creation Date:
2024-05-05 @ 10:00 AM
Last Modification Date:
2024-10-26 @ 9:02 AM
Study NCT ID:
NCT00002174
Status:
COMPLETED
Last Update Posted:
2005-06-24
First Post:
1999-11-02
Brief Title:
Further Evaluation of Thalidomides Ability to Potentiate the Immune Response to HIV-Infected Patients
Sponsor:
Louisiana State University Health Sciences Center in New Orleans
Organization:
NIH AIDS Clinical Trials Information Service
Study Overview
Official Title:
Further Evaluation of Thalidomides Ability to Potentiate the Immune Response to HIV-Infected Patients
Status:
COMPLETED
Status Verified Date:
1997-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To determine if Thalidomide modulates the production of HIV-suppressor factors MIP-1 alpha MIP-1 beta Rantes and TH1 type cytokines IL-12 and INF-gamma in HIV-infected patients and alters viral load
Detailed Description:
Patients will be divided 5 per group into Groups I II III and IV Groups I and II will include patients who have decided not to take anti-retro viral drugs Groups III and IV will include patients receiving the same types of antiretroviral drugs Patients in groups I and III will receive thalidomide while patients in group II and IV will receive placebo The placebo capsules will be the same color as the thalidomide capsules and will contain glucose powder Patients will ingest one capsule of thalidomide at 9 PM daily on days 0 1 2 3 4 5 and 6
Study Oversight
Has Oversight DMC:
Is a FDA Regulated Drug?:
Is a FDA Regulated Device?:
Is an Unapproved Device?:
Is a PPSD?:
Is a US Export?:
Is an FDA AA801 Violation?: